CTXR
Citius Pharmaceuticals, Inc.
+0.03 (+5.41%)0.59USD122K成交股數16.2M市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-08-14下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 9 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 1.5M | 1.7M | 3.9M | – | – | – | – | – | – | – | – | – |
| 營業成本 | 492K | 329K | 789K | – | – | – | – | – | – | – | – | – |
| 毛利 | 1.0M | 1.3M | 3.2M | – | – | – | – | – | – | – | – | – |
| 毛利率 | 67.1% | 80.3% | 80.0% | – | – | – | – | – | – | – | – | – |
| 研發費用 | 1.1M | 1.6M | 1.6M | 1.6M | 1.6M | 3.8M | 2.1M | 2.8M | 3.6M | 2.6M | 2.9M | 3.8M |
| 銷售管理費用 | 6.1M | 26.4M | 5.7M | 3.9M | 4.4M | 4.8M | 5.4M | 4.8M | 4.3M | 3.7M | 4.2M | 3.7M |
| 營業利益 | −11.7M+34% | −32.2M+186% | −9.0M-10% | −8.4M-21% | −8.8M-20% | −11.3M+21% | −10.0M-1% | −10.6M+23% | −11.0M | −9.3M | −10.1M | −8.7M |
| 營業利益率 | -785.4% | -1,931.0% | -228.7% | – | – | – | – | – | – | – | – | – |
| 稅後淨利 | −11.9M+30% | −28.1M+144% | −9.4M-9% | −8.7M-17% | −9.2M+8% | −11.5M-225% | −10.3M+3% | −10.6M+25% | −8.5M | 9.2M | −9.9M | −8.5M |
| 淨利率 | -797.9% | -1,685.9% | -238.2% | – | – | – | – | – | – | – | – | – |
| 稀釋 EPS | -0.34-57% | -0.95-25% | -0.38-71% | -0.01-99% | -0.80-40% | -1.27-12% | -1.30-76% | -1.57+2517% | -1.34 | -1.45 | -5.42 | -0.06 |
| 稀釋股數 | 26.2M | 22.4M | 21.5M | 11.1M | 11.0M | 8.6M | 7.5M | 7.0M | 6.4M | 6.4M | 6.1M | 154M |
資產負債表 期末餘額
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 17.0M | 4.6M | 7.7M | 4.3M | 6.1M | 26K | 1.1M | 17.9M | 12.6M | 20.3M | 26.5M | 33.3M |
| 應收帳款 | 686K | 1.1M | 4.0M | – | – | – | – | – | – | – | – | – |
| 存貨 | 22.6M | 22.7M | 22.6M | 22.3M | 17.2M | 15.3M | 14.4M | – | – | – | – | – |
| 總資產 | 142M | 133M | 140M | 131M | 128M | 121M | 121M | 97.1M | 90.7M | 97.4M | 104M | 110M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 66.3M | 63.5M | 46.9M | 53.4M | 60.1M | 57.9M | 51.8M | 10.8M | 10.7M | 12.1M | 12.2M | 12.1M |
| 股東權益 | 66.6M | 61.5M | 80.0M | 67.6M | 65.1M | 60.7M | 65.4M | 85.7M | 79.4M | 84.7M | 90.8M | 97.7M |
| 負債比 | 46.6% | 47.9% | 33.4% | 40.8% | 47.1% | 47.7% | 42.9% | 11.1% | 11.8% | 12.4% | 11.8% | 11.0% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | – | −13.0M+175% | – | – | – | −4.7M | – | – | −6.1M | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | – | – | −39.7M | –% | -3.38 | – |
| FY2024 | – | – | −39.4M | –% | -5.97 | – |
| FY2023 | – | – | −32.5M | –% | -5.57 | – |
| FY2022 | 90K | 0.0% | −33.6M | -37,378.5% | -0.23 | – |
| FY2021 | 90K | 0.0% | −23.1M | -25,616.0% | -0.23 | −24.3M |
| FY2020 | 90K | 0.0% | −17.5M | -19,497.9% | -0.45 | −16.9M |
| FY2019 | 90K | +20.0% | −15.6M | -17,291.3% | -0.77 | – |
| FY2018 | 75K | – | −12.5M | -16,715.5% | -1.17 | – |